KARD (Kardigan) EV-to-EBITDA: (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KARD Kardigan Inc KARD
11 GF Score
Price $20.46
! 1 Warning Sign
View Full Analysis

What is Kardigan EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kardigan's enterprise value is $1,554.69 Mil. Kardigan does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Kardigan's EV-to-EBITDA at this moment.

The historical rank and industry rank for Kardigan's EV-to-EBITDA or its related term are showing as below:

KARD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.99   Med: 0   Max: 0
Current: -7.93
KARD's EV-to-EBITDA is ranked worse than
100% of 415 companies
in the Biotechnology industry
Industry Median: 11.92 vs KARD: -7.93

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2026-08-04), Kardigan's stock price is $20.46. Kardigan does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Kardigan's PE Ratio (TTM) at this moment.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

Kardigan  (NAS:KARD) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Kardigan's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=20.46/
=

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Kardigan EV-to-EBITDA Related Terms

Kardigan EV-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Kardigan's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kardigan EV-to-EBITDA Chart

Kardigan Annual Data
Trend Dec24 Dec25
EV-to-EBITDA
0.00 0.00

Kardigan Semi-Annual Data
Dec24 Dec25
EV-to-EBITDA 0.00 0.00

KARD vs OCUL, GHRS, FTRE: EV-to-EBITDA Comparison

For the Biotechnology subindustry, Kardigan's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kardigan EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kardigan's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Kardigan's EV-to-EBITDA falls into.


KARD
11GF Score
Kardigan Inc KARD
EV-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kardigan EV-to-EBITDA Calculation

Kardigan's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1554.685/
=

Kardigan Business Description

Address 506 Carnegie Center Drive, Suite 201, Princeton, NJ, USA, 08540
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
11GF Score

Get the complete analysis for KARD

EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.46
Price